ARCHIVES

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

Preventive Surgery Cuts Risk Of Breast, Ovarian Cancers

May 31, 2002

FDA’s Kweder cites Society of Professional Journalists’ Code of Ethics–incorrectly, SPJ says.

March 4, 2005

Research vs. Delivery? Advisors Debate NCI Role In Review of Community Program.

November 21, 2008

Politics May Play Role In FDA’s Avastin Decision

May 27, 2011

FASEB Urges Congress To Fund Stem Cell Research.

July 27, 2001

In Brief : Patricia LoRusso Named Associate Director Of Innovative Medicine at Yale Cancer Center

June 20, 2014